Differential Impacts of Platelet-Rich Plasma and Hyaluronic Acid on miR-132 Modulation, Inflammatory Cytokines (IL-1β and IL-6), and Functional Recovery in Knee Osteoarthritis: A Randomized Controlled Trial
- 1Department of Orthopaedic and Traumatology, Bhayangkara Hospital, Makassar, Indonesia.
- 2Department of Clinical Microbiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
- 3Department of Orthopaedics, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Abstract
The objective of the study was to examine differences in miR-132 gene expression, cytokine levels (IL-1β and IL-6), and functional outcomes in patients with knee osteoarthritis following treatment with PRP and HA. This study employed an exploratory, randomized, open-label, parallel-group interventional research design, where 131 participants were initially recruited. The trial was conducted from January 2023 to January 2024, at Bhayangkara Hospital Makassar, the South Sulawesi Regional Police Headquarters, and the HUM-RC Laboratory, Faculty of Medicine, Hasanuddin University. The samples of peripheral blood were collected at baseline and five days after treatment. miR-132 expression RT-PCR, cytokine levels, and clinical outcomes (VAS and WOMAC scores) were evaluated. PRP significantly decreased miR-132 expression (p = 0.000121), whereas HA (p = 0.775) and controls (p = 0.874) showed no significant changes. Between-group analysis revealed a significant difference between the PRP and control groups (p = 0.0105). IL-1β significantly decreased only in the HA group (p < 0.001). Both treatment groups had lower IL-1β than control group on day five (p < 0.0001). Meanwhile, no significant within- or between-group differences were observed for IL-6. PRP (p = 0.006) and HA (p < 0.001) significantly reduced VAS scores, but only PRP improved WOMAC (p = 0.035). However, the functional outcomes did not surpass the minimal clinically important difference (MCID) thresholds. PRP treatment significantly reduced miR-132 expression and improved functional outcomes to a certain extent, while HA appeared to affect IL-1β modulation with minimal functional effects.
Related
- CD44-targeted hyaluronic acid nanohydrogels enhance macrophage uptake and preserve the anti-inflammatory efficacy of dexamethasone
- Spatial macrophage-fibroblast interactions in osteoarthritis synovium: inflammatory and fibrotic niches
- Gastroprotective effects of chlorella derived lutein via anti-inflammatory antioxidant and acid enzyme modulation
- MSC-derived extracellular vesicles for spinal cord injury: inflammatory microenvironment modulation, stage-dependent repair mechanisms, and translational challenges
- Exploring the therapeutic potential of Erycibe paniculata (Roxb.): metabolite profiling and antimalarial, anticancer, and modulation of NF-κB signaling pathway for anti-inflammatory activities
BibTeX
@article{chaniago2026differential,
title = {{Differential Impacts of Platelet-Rich Plasma and Hyaluronic Acid on miR-132 Modulation, Inflammatory Cytokines (IL-1β and IL-6), and Functional Recovery in Knee Osteoarthritis: A Randomized Controlled Trial}},
author = {Hendrian Chaniago and Muhammad Nasrum Massi and Muhammad Andry Usman and Muhammad Phetrus Johan},
journal = {International Journal of Molecular and Cellular Medicine},
year = {2026},
month = jun,
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Differential Impacts of Platelet-Rich Plasma and Hyaluronic Acid on miR-132 Modulation, Inflammatory Cytokines (IL-1β and IL-6), and Functional Recovery in Knee Osteoarthritis: A Randomized Controlled Trial
AU - Hendrian Chaniago
AU - Muhammad Nasrum Massi
AU - Muhammad Andry Usman
AU - Muhammad Phetrus Johan
PY - 2026
DA - 2026/06/01
JO - International Journal of Molecular and Cellular Medicine
AB - The objective of the study was to examine differences in miR-132 gene expression, cytokine levels (IL-1β and IL-6), and functional outcomes in patients with knee osteoarthritis following treatment with PRP and HA. This study employed an exploratory, randomized, open-label, parallel-group interventional research design, where 131 participants were initially recruited. The trial was conducted from January 2023 to January 2024, at Bhayangkara Hospital Makassar, the South Sulawesi Regional Police Headquarters, and the HUM-RC Laboratory, Faculty of Medicine, Hasanuddin University. The samples of peripheral blood were collected at baseline and five days after treatment. miR-132 expression RT-PCR, cytokine levels, and clinical outcomes (VAS and WOMAC scores) were evaluated. PRP significantly decreased miR-132 expression (p = 0.000121), whereas HA (p = 0.775) and controls (p = 0.874) showed no significant changes. Between-group analysis revealed a significant difference between the PRP and control groups (p = 0.0105). IL-1β significantly decreased only in the HA group (p < 0.001). Both treatment groups had lower IL-1β than control group on day five (p < 0.0001). Meanwhile, no significant within- or between-group differences were observed for IL-6. PRP (p = 0.006) and HA (p < 0.001) significantly reduced VAS scores, but only PRP improved WOMAC (p = 0.035). However, the functional outcomes did not surpass the minimal clinically important difference (MCID) thresholds. PRP treatment significantly reduced miR-132 expression and improved functional outcomes to a certain extent, while HA appeared to affect IL-1β modulation with minimal functional effects.
SN - 2251-9637
SN - 2251-9645
ER -